Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells

The PDE4B inhibitor Nerandomilast demonstrates potent therapeutic effects in a preclinical IIM-ILD model, alleviating both myositis and pulmonary pathology. Its efficacy is mechanistically linked to the direct modulation of B cells, achieved by elevating intracellular cAMP and subsequently reprogramming key signaling networks to inhibit B cell activation, proliferation, and pathogenic differentiation into antibody-producing plasma cells. These findings highlight Nerandomilast as a promising candidate for the treatment of IIM-ILD.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-02-18
DOI
https://doi.org/10.3389/fimmu.2026.1771007
Primary Topic
Phosphodiesterase function and regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells

Xueze Liu, Yujie He, Huihui Li, Zhongyi Yang et al.
Frontiers in Immunology
Phosphodiesterase function and regulation
article

Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells

Xueze Liu, Yujie He, Huihui Li, Zhongyi Yang, Yayue Hu, Yuming Liu, Xiaohe Li, Chunyu Kong, H Q Zhou, Songtao Gu, Se-rigeleng, Xiaoting Gu, Jiayang Yu, Weitao Yang, Cheng Yang
article en

Abstract

The PDE4B inhibitor Nerandomilast demonstrates potent therapeutic effects in a preclinical IIM-ILD model, alleviating both myositis and pulmonary pathology. Its efficacy is mechanistically linked to the direct modulation of B cells, achieved by elevating intracellular cAMP and subsequently reprogramming key signaling networks to inhibit B cell activation, proliferation, and pathogenic differentiation into antibody-producing plasma cells. These findings highlight Nerandomilast as a promising candidate for the treatment of IIM-ILD.

Frontiers in ImmunologyVol. 17
Nankai University (CN), Tianjin First Center Hospital (CN), Tianjin Institute of Pharmaceutical Research (China) (CN), Xuzhou Central Hospital (CN), Tianjin Chest Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Tianjin Medical University (CN), Xuchang University (CN)
Good health and well-being
Openalex Percentile: Top 52%
Phosphodiesterase function and regulation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells — Xueze Liu, Yujie He, et al. · Frontiers in Immunology (2026) | TGRS Research Map | TGRS